26th Nov 2009 13:30
Sinclair Pharma plc (the "Company") Annual Information Update
26 November 2009, Godalming, UK: Sinclair Pharma Plc,the international specialty pharma company, is pleased to provide an annual information update in accordance with the requirements of Prospectus Rule 5.2.1R, of information that has been published or made available to the public for the period from 16 November 2008 to date. The information referred to in this update was current at the time the information was published but some information may now be out of date.
1. Announcements made via a Regulatory Information Service
The Company made the following regulatory announcements via the Regulatory News Service on or around the dates indicated:
Date Announcement 24/11/2009 Publication of Prospectus 23/11/2009 Jerry Randall to step down as CFO 19/11/2009 Interim Management Statement 12/11/2009 Sinclair, Orapharma terminate US Decapinol agreement 11/11/2009 Result of General Meeting 02/11/2009 Annual Report & Accounts 29/10/2009 New Debt Facility 12/10/2009 Acquisition of Flammazine and Flammacerium from Solvay 12/10/2009 Preliminary results for the year ended 30 June 2009 05/10/2009 Re-Convertible Unsecured Loan Note 23/09/2009 Re-Convertible Unsecured Loan Note 23/09/2009 INVESCO Limited Rule 8.3 - Sinclair Pharma plc 22/09/2009 Statement re Share Price Movement 14/09/2009 Second Price Monitoring Extension 14/09/2009 Price Monitoring Extension 07/09/2009 Placement of Convertible Unsecured Loan Notes 28/08/2009 Total Voting Rights 17/08/2009 Blocklisting Interim Review 04/08/2009 Sebclair launched in US 22/07/2009 Trading update for the year ending 30 June 2009 15/06/2009 Holding(s) in Company 18/05/2009 Interim Management Statement 22/04/2009 Change of Adviser 18/03/2009 Second Price Monitoring Extension 18/03/2009 Price Monitoring Extension 03/03/2009 Change of Adviser 26/02/2009 Interim Results 20/02/2009 Sinclair Pharma signs agreements with BMG Pharma 13/02/2009 Notice of Results 09/02/2009 Blocklisting Interim Review 05/02/2009 Holding(s) in Company 04/02/2009 Sinclair strengthens European sales and marketing 23/01/2009 Holding(s) in Company 07/01/2009 Agreement signed with Graceway for Atopiclair in US 31/12/2008 Total Voting Rights 22/12/2008 Sinclair Pharma announces sales collaboration 12/12/2008 Director/PDMR Shareholding 11/12/2008 Grant of Share Awards under Long-term Incentive Plan 08/12/2008 Result of AGM 08/12/2008 Placing 28/11/2008 Total Voting Rights 20/11/2008 Annual Information Update 18/11/2008 Additional Listing
2. Documents filed at Companies House
Type Date Description MG02 25/11/2009 Declaration of satisfaction in full or in part of a mortgage or charge MG02 25/11/2009 Declaration of satisfaction in full or in part of a mortgage or charge 88(2) 14/09/2009 Issue of 9,189 ordinary 1p shares at 1p each on 30 June 2009 88(2) 06/03/2009 Issue of 7,000,000 ordinary 1p shares at 16p each on 8 December 2008 88(2) 06/03/2009 Issue of 1,956,521 ordinary 1p shares at 23p each on 12 November 2008 88(2) 02/03/2009 Capitals not rolled up 88(2) 23/01/2009 Issue of 400,000 ordinary 1p shares at 23p each on 18 November 2008 363a 19/12/2008 Annual Return AA 17/12/2008 Group of companies accounts made up to 30 June 2008 288b 10/12/2008 Resignation of Ralph Steven Harris as a director RES10 10/12/2008 Authorised allotment of shares and debentures RES01 10/12/2008 Alteration to memorandum and articles RES09 10/12/2008 Authority - purchase shares other than from capital RES11 10/12/2008 Disapplication of pre-emption rights
Copies of documents filed at Companies House can be obtained from the Companies House website at www.companieshouse.gov.uk or Companies House, Crown Way, Cardiff F14 3UZ.
3. Additional Documents
The Company submitted copies of the following documents to the UK Listing Authority, which have also been provided to shareholders:
Date Document 24/11/2009 Prospectus in connection with the acquisition of the Solvay Products, firm placing and placing and open offer of 56,731,322 new ordinary shares at 32 pence per new ordinary share and Notice of General Meeting 02/11/2009 Annual report and accounts for the year ended 30 June 2008 and Notice of Annual General Meeting 26/02/2009 Interim report for the six months to 31 December 2008
All of the documents listed above can be obtained from the Company's website www.sinclairpharmair.com and are available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25, The North Colonnade, Canary Wharf, London E14 5HS.
- Ends -
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Singer Capital Markets Ltd Tel: +44 (0)20 3205 7500
Shaun Dobson
Claes Spang
Capital MS&L Tel +44 (0)20 7307 5340
Mary ClarkAnna MitchellNotes to Editors:
About Sinclair Pharma Plc: www.sinclairpharma.com.
Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat dermatological, oral care and gynaecological diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is already present in France, Italy and Spain, and a complementary marketing partner network that spans more than 90 countries.
This annual information update is required by, and is being made pursuant to, Article 10 of the Prospectus Directive as implemented in the UK by Prospectus Rule 5.2 and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information which it contains. The information is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Further, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to in it, constitutes, by virtue of this communication, an offer of any securities addressed to any person and it should not be relied on by any person.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
vendorRelated Shares:
Sinclair Pharma